Jeil Pharma Holdings Targets Price-to-Book Ratio of 0.5 by 2028

• Jeil Pharma Holdings unveiled an October 22, 2026, plan targeting a price-to-book ratio of 0.5 times by 2028.
• The dividend payout ratio is targeted at about 20%, supported by a sustainable policy balancing growth with financial stability.
• Core subsidiary Jeil Pharmaceutical will continue shifting toward product-led sales and improving investment efficiency to raise operating profit.
• Follow-on drug pipeline development will support long-term growth, while Jeil Health Science will seek to improve operating profit through sales recovery.
• Treasury shares will be used to enhance corporate value; investment properties will undergo regular reviews to improve cash generation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jeil Pharma Holdings Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261022800657), on October 22, 2026, and is solely responsible for the information contained therein.